These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9491207)

  • 1. In vitro effects of prostaglandin E2 or indomethacin on the proliferation of lymphokine-activated killer cells and their cytotoxicity against bladder tumor cells in patients with bladder cancer.
    Wang Z; Chen Y; Zheng R; Qin D; Chen X; Wang Y; Liu G
    Prostaglandins; 1997 Nov; 54(5):769-79. PubMed ID: 9491207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tretinoin or retinol enhancement of lymphokine-activated killer cell proliferation and cytotoxicity against human bladder cancer cells in vitro.
    Wang ZP; Zheng RL; Chen YR; Liu GD
    Zhongguo Yao Li Xue Bao; 1997 Nov; 18(6):522-4. PubMed ID: 10322910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulating effect of mitomycin or cisplatin on lymphokine-activated killer cell proliferation and antitumor activity to bladder cancer cell lines in vitro.
    Wang ZP; Qing DS; Shi BG; Chen YR; Liu GD
    Zhongguo Yao Li Xue Bao; 1998 Jul; 19(4):369-72. PubMed ID: 10375787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of reactive oxygen species on lymphokine-activated killer cells in patients with bladder cancer.
    Wang ZP; Chen YR; Zheng RL; Lu JZ; Wang JJ
    Acta Pharmacol Sin; 2002 Mar; 23(3):257-62. PubMed ID: 11918852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of TNF-alpha and IFN-alpha on the proliferation and cytotoxicity of lymphokine-activated killer cells in patients with bladder cancer.
    Wang Z; Cheng Y; Zheng R; Qin D; Liu G
    Chin Med J (Engl); 1997 Mar; 110(3):180-3. PubMed ID: 9594335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basic fibroblast growth factor enhanced LAK cell cytotoxicities against human bladder neoplasm cells.
    Wang ZP; Duan GL; Chen YR; Qin DS; Liu GD; Niu HG
    Zhongguo Yao Li Xue Bao; 1999 Mar; 20(3):276-8. PubMed ID: 10452107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
    Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
    Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The augmentation of lymphokine-activated killer cell activity by indomethacin in vitro is not mediated by prostaglandin E2 suppression.
    Chao TY; Ting CS; Chu TM; Yeh MY
    Proc Natl Sci Counc Repub China B; 1993 Oct; 17(4):138-42. PubMed ID: 8171164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of indomethacin on lymphokine-activated killer cell activities in cancer patients.
    Chao TY; Ting CS; Yeh MY; Chang JY; Wang CC; Chu TM
    Tumour Biol; 1995; 16(4):230-42. PubMed ID: 7604204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells.
    Hermann GG; Petersen KR; Steven K; Zeuthen J
    J Clin Immunol; 1990 Nov; 10(6):311-20. PubMed ID: 1707414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
    Hermann GG; Zeuthen J; Claësson MH
    Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines.
    Jackson AM; Hawkyard SJ; Prescott S; Ritchie AW; James K; Chisholm GD
    J Urol; 1992 Jan; 147(1):207-11. PubMed ID: 1729534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
    Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relative resistance of lymphokine activated killer cells to suppression by prostaglandins and glucocorticoids.
    Imir T; Sibbitt W; Bankhurst A
    Prostaglandins Leukot Med; 1987 Jul; 28(2):111-8. PubMed ID: 3498171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines.
    Wang MH; Flad HD; Böhle A; Chen YQ; Ulmer AJ
    Immunol Lett; 1991 Mar; 27(3):191-7. PubMed ID: 2060970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin E2 from macrophages of murine splenocyte cultures inhibits the generation of lymphokine-activated killer cell activity.
    Ohnishi H; Lin TH; Nakajima I; Chu TM
    Tumour Biol; 1991; 12(2):99-110. PubMed ID: 2028183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells.
    Schadendorf D; Böhm M; Möller P; Grünewald T; Czarnetzki BM
    J Invest Dermatol; 1994 Jun; 102(6):838-42. PubMed ID: 8006445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of OK-432 on the proliferation and cytotoxicity of lymphokine-activated killer (LAK) cells.
    Yamamoto K; Tanaka R; Yoshida S; Ono K; Mori H; Taniguchi Y; Oda T; Watanabe T
    J Immunother; 1999 Jan; 22(1):33-40. PubMed ID: 9924697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2.
    Leung KH
    Cell Immunol; 1989 Oct; 123(2):384-95. PubMed ID: 2507171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.